Physician profile
Allison Pullen
NPI 1477915742
$4,349.57
in general payments reported to CMS, 2019-2025
19 companies · $2,205 in 2025
The $2,205 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $215 · 2022: $279 · 2023: $488 · 2024: $1,162 · 2025: $2,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,855.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,084.67 | 2021-2025 | Livdelzi |
| Madrigal Pharmaceuticals | $781.68 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $502.76 | 2023-2025 | Xifaxan |
| Mallinckrodt Hospital Products INC. | $468.16 | 2022-2025 | Terlivaz |
| Ipsen Biopharmaceuticals, INC | $459.45 | 2024-2025 | Iqirvo |
| Janssen Biotech, INC. | $271.62 | 2025 | Tremfya |
| Novo Nordisk INC | $182.93 | 2025 | Wegovy |
| Janssen Scientific Affairs, LLC | $120.51 | 2025 | Tremfya |
| Abbvie INC. | $106.18 | 2022-2023 | |
| Intercept Pharmaceuticals, INC. | $72.23 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $62.97 | 2023-2024 | Farxiga |
| Mirum Pharmaceuticals, INC. | $44.55 | 2025 | Livmarli, Cholbam, Chenodal |
| Boston Scientific Corporation | $44.10 | 2023 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Sandoz INC. | $31.65 | 2024 | Hyrimoz |
| Lilly USA, LLC | $31.40 | 2025 | Omvoh |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $24.23 | 2025 | Gattex |
| Phathom Pharmaceuticals, INC. | $24.08 | 2024 | Voquezna |
| Dynavax Technologies Corporation | $18.75 | 2025 | Heplisav-B |
| W. L. Gore & Associates, INC. | $17.65 | 2023 | Gore Cardioform Septal Occluder |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Pullen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.